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Abstract 
 
Cancer and autoimmune diseases are often associated in the same individual. The functional link between 
immune system and cancer development is only partially known. Even though the immune system can 
control the development of cancer through immune surveillance, cancer cell itself can escape immune 
surveillance. Actually, it is debated whether autoimmune diseases have to be regarded as cancer cause or its 
consequence. 
In particular, autoimmune thyroiditis and thyroid cancer (in particular, papillary thyroid cancer) are a 
fascinating model of this complex relationship. In the present review, we describe what has been reported by 
now in literature about autoimmune thyroiditis and papillary thyroid cancer, and on the basis of available 
data, we try to clarify the present knowledge. 
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Cancer and Immunity 
 
Cancer and immunity show multiple points of interplay. Their functional relationship is complex and the 
final outcome could be extremely different. All the various characters playing in the immune response are 
somehow involved in cancer, e.g. antigen presenting cells, antibodies, B-cells, T-cells, cytokines, etc. 
Linkage between cancer and immune system diseases is also known but its pathogenetic meaning is quite far 
to be fully understood.  
The immune system is programmed to distinguish between self and non-self, in order to react against 
extraneous threat while avoiding immune reaction to self. However, when the mechanism of immune 
tolerance is somehow imbalanced, autoimmunity or cancer or even both can occur.  
The immune system can control the development of cancer through immune surveillance, but, despite this, 
cancer cells can develop several strategies to escape immune surveillance. During cancer development, the 
innate immunity comprising antigen presenting cells such as dendritic cells and macrophages as well as 
natural killer cells become tolerant. Furthermore, T cells that constitute the adaptive immune response 
undergo apoptosis; the production of immunosuppressive cytokines, in addition, makes them unable to 
interact with antigen presenting cells. The result is an environment favorable to tumor outgrowth [1]. In more 
details, the balance/unbalance between cancer and immune cells results in three different scenarios: 1) 
elimination of tumor, 2) equilibrium; 3) escape immune surveillance (Figure 1). In the elimination phase, 
during early tumor development, cancer cells present tumor-specific antigens recognized by the immune 
system [2]. Inflammatory cytokines (e.g. IFNγ and IL12) produced and released from tumor cells, 
surrounding stromal cells and macrophages, attract natural killer cells and induce maturation of dendritic 
cells that will be able to present tumor-associated antigens to T cells leading to the ultimate killing of tumor 
cells.  In the equilibrium phase, the immune system through IFNγ-mediated cytotoxicity kills the highly-
immunogenic tumor cells but this may select clones of low-immunogenic cells that are more resistant to 
immune cell-mediated killing. This phase may last for a long time (months or years) and its final result could 
be either elimination of tumor cells or escape from immune surveillance [3]. Lastly, the escape phase is 
characterized by the development of cancer that becomes clinically evident. Cancer cells are able to produce 
highly immunosuppressive cytokines such as TGFβ and IL10 to inhibit T cell response and induce T cell 
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apoptosis, to block dendritic cell maturation and, finally, to induce T-regulatory (T reg) cells that further 
suppress the immune system. 
 
Cancer development is often concomitant with autoimmunity phenomena. A wide range of autoantibodies 
can be produced and detected in serum of different type of cancer patients. Antibodies can be directed 
against tumor-associated antigens (e.g. antibodies to oncoproteins or tumor suppression genes), or to 
antigens not directly associated to tumor (e.g. anti-nuclear and anti-thyroid antigens). 
Cancer development after or together to autoimmune disease could be related to the prolonged and often 
severe immune stimulus of autoimmune disease. Moreover, paraneoplastic autoimmune disorders 
characterized by rheumatic manifestations can precede, accompany or follow the onset of tumor. It was also 
reported that paraneoplastic rheumatism could be the basis for symptoms of systemic autoimmune diseases 
[4]. Autoimmunity manifestations can be associated to haematologic malignancies, breast cancer, colon 
cancer, melanoma and thyroid cancer. 
 
Thyroid Cancer and AutoImmunity: Epidemiological and Clinical Overview 
The relationship between chronic inflammatory diseases and carcinogenesis has been widely investigated. 
Following the first hypothesis formulated by Wirchow at the end of XIX century, strong evidences were then 
collected linking up intestinal chronic inflammatory diseases and colorectal cancer, asbestosis and 
mesothelioma, chronic HBV or HCV infections and hepatocellular carcinoma, chronic obstructive 
pulmonary disease and lung cancer. Moreover, immune cells (tumor associated lymphocytes, tumor-
associated macrophages, mast cells and dendritic cells) were identified within neoplastic lesions and 
recognized as determinant factors of tumor growth and tumor-induced immune tolerance [5,6], as already 
reported.  
Also, the association between autoimmune thyroid diseases (AITDs) and thyroid cancer (TC) has been 
widely debated in the last decades. 
TC can arise both from follicular or parafollicular thyroid cells and represents the most frequent endocrine 
neoplasia. Three histotypes originate from follicular cells: well-differentiated (WDTC), poorly-differentiated 
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(PDTC) and anaplastic (ATC) thyroid carcinoma. WDTC are categorized in papillary (PTC) and follicular 
carcinoma (FTC). The incidence of TC in the last decades is significantly increased, due to the increased 
number of WDTC diagnosed in the initial stadium. This observation seems to be confirmed by the stability 
of the mortality rate due to TC [7]. Medullary thyroid carcinoma (MTC), originating from parafollicular C-
cells shows a different pathogenesis and, although sporadic in the majority of cases, in about 20% of cases is 
due to a germline mutation in the RET proto-oncogene in the contest of genetic syndromes (MEN2, FMTC). 
Instead, de novo RET/PTC translocations, BRAF, RAS, RET and TRKA mutations are the most frequently 
described in WDTC [8]. 
AITDs are a group of quite common pathological conditions with different clinical presentations, either 
hypothyroidism or hyperthyroidism, due to an immune system deregulation that leads to a T-cell mediated 
damage against the thyroid gland. Both the main types of AITDs, Hashimoto’s Thyroiditis (HT) and Graves’ 
Disease (GD), are characterized by lymphocytic infiltration of the parenchyma. The prevalence of AITDs is 
estimated to be about 5% in the general population, with a female/male ratio of 4-10/1; the prevalence of 
thyroid auto-antibodies without clinical manifestations is probably higher [9]. Antibodies to thyroperoxidase 
(TPO-Ab) are considered the most sensitive serological marker of HT and probably they also have a 
correlation with the grade of lymphocyte infiltration within the thyroid gland [10]. Antibodies to 
thyroglobulin (Tg-Ab), although less sensitive and specific for the diagnosis of HT, have been hypothesize to 
reflect the initial immune response and, consequently, can be the only ones present in the early phase of the 
process [10]. TSH receptor antibodies (TRAb) are detectable in almost all cases of GD and responsible for 
the development of hyperthyroidism 9.  
From an epidemiological perspective, female sex and iodine levels are key factors in the development of 
both AITDs and thyroid nodules [9].  
Since Dailey et al [11] in 1955 firstly hypothesized the association between AITDs and TC, a high number of 
studies focused on this field have been published. HT was frequently associated with an increased incidence 
of PTC [12,13] but some studies showed contrasting results [14-16]. More controversial is the association 
between GD (and hyperthyroidism) and the onset of TC [17].  
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As recently underlined by Fiore et al in their review [16], different degrees of association were found if 
cytological or histological series were considered [18-20]. As hypothesized by the Authors themselves [19], 
this result could be strongly influenced by a selection bias: if cytological examination is usually performed in 
patients with ultrasound suspicious thyroid nodules (i.e. with high a priori probability of malignancy), 
thyroidectomy, instead, is frequently performed in patients with GD (to treat hyperthyroidism) or due to 
compressive symptoms in subjects with large nodular goiter and coexisting AITD.  
Moreover, it should also be taken into account the heterogeneity in AITD definitions adopted in different 
studies, ranging from the presence of serum circulating thyroid antibodies with or without hypothyroidism to 
the presence of lymphocytic infiltration in the thyroid gland (also in the absence of thyroid antibodies) [16,]. 
Latrofa et al hypothesized that differences in the associations of these conditions with TC could be due to 
different epitope pattern of TgAb [21].  
Chronic lymphocytic thyroid infiltration (CLTI) has been reported to be significantly higher in patients with 
PTC than in those with nodular goiter [20,22]. In term of prognosis, the final result of the complex 
interactions between immune system and tumor cell still remains debated. The presence of lymphocytes has 
been interpreted as an active immune host response or just as a coexisting condition. Accordingly, only few 
studies reported a worse prognosis of PTC associated with CLTI, but the great majority agree with the 
hypothesis that the presence of CTLI may lead to a better prognosis or not influence the clinical outcome of 
PTC [6,13,17,23]. Kim et al, in a study aimed to define the role of CLTI according to BRAF V600E 
mutation status in a cohort of PTC patients, concluded that CLTI was an independent predictor for low 
prevalence of both extra-thyroidal extension and central compartment nodal metastases, regardless BRAF 
mutation status [24]. Nevertheless, higher prevalence of multifocal or bilateral lesions was reported in TC 
patients with coexisting CLTI [24] and recently Iliadou el al [25] showed that children and adolescents with 
CLTI presented more frequently familial PTC, even if no differences in outcome were found with respect to 
the presence of CLTI. In this regard, it should finally be noted that TC histotypes with a worse prognosis 
(PDTC, ATC) are characterized by a very reduced lymphocyte infiltration [26].  
The increased levels of thyroid stimulating hormone (TSH) have been hypothesized to be a different 
mechanism underlying the linkage between PTC and AITDs [27]. Indeed, hypothyroidism represents the 
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most common clinical presentation of AITDs and TSH is the major growth factor for thyrocytes. Several 
studies demonstrated the close relationship between TSH serum levels and the risk of TC [28,29], and the 
association was confirmed for increasing TSH values but still within the reference ranges [29].  
Even though controversial, literature about the linkage between AITDs and TC is wide, while the reports 
about a potential relationship between AITDs and MTC (or thyroidal C-cells hyperplasia) are nearly 
anecdotal and - beyond suggestions that can originate from small series or case reports - they do not allow to 
draw definitive conclusions [30]. 
 
 
Thyroid Cancer and AutoImmunity: Cellular and Molecular Suggestions 
 
Dendritic Cells (DCs) 
Either in PTC and in AITDs prominent leukocytic infiltration of thyroid tissue is present [24]. In HT the first 
step is infiltration of dendritic cells (DCs) and then of leucocytes. Actually, DCs are observed also in PTC, 
isolated in the background and/or in association with tumor cells [31]. 
DCs are believed to play a central role in autoimmune and neoplastic thyroid diseases. Generally speaking, 
DCs are of two different types: plasmacytoid DCs (pDCs) and myeloid DCs (mDCs); pDCs are the main 
source of IFNs and regulate T cells generation and function; mDCs mainly promote T helper function and 
induce IL-12 and IL-23 secretion [32]. 
As far as AITDs are concerned, pDCs are believed to have a specific role. Actually, DCs were reported to be 
increased in thyroid infiltrates in all main autoimmune thyroid diseases, as HT and GD. In particular, mature 
DCs were observed in connective tissue while immature DCs were mainly located around thyroid follicles. 
The evaluation of peripheral blood DC subpopulation in comparison to thyroid gland [33] evidenced that 
peripheral pDCs are significantly lower in autoimmune thyroid diseases than in healthy controls. Peripheral 
pDCs, in addition, are characterized by an increased in vitro 
DCs are indeed characterized by higher Fas ligand expression in comparison with peripheral pDCs.  
It was claimed that molecules involved in chronic inflammation can also have a considerable function in 
tumor induction and development. DCs have also been proposed to participate in the development of thyroid 
cancer. In PTC rich DCs infiltrates were reported in all different histotypes [26]. DCs present a precise 
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distribution in tumors; immature DCs are generally located within PTC nodules, while mature DCs are 
observed around tumor [31,34]. It is still controversial whether DCs are linked to a better or worst prognosis 
of PTC. It was suggested that the extent of DC infiltrate in PTC is positively associated with favorable 
clinical course [35]. From the other hand, observation by other Authors pointed out that short-term disease-
free survival while correlating positively with thyroiditis grade did not with the number of infiltrating DCs 
[36]. It was therefore suggested that DCs recovered in PTC do not have any defensive action, but could be 
involved in tumor immune escape process. DCs are, therefore, for sure involved in PTC, but their precise 
role and significance still have to be elucidated. 
 
Cellular and Humoral Immune Response 
The autoimmune process starts in thyroiditis with DC infiltration followed by additional leucocytes; as 
already mentioned, DCs were observed also in PTC, either in the background and/or close to tumor cells [31] 
and their presence can account for further immune cell infiltration. In thyroid the presence of leukocyte 
infiltration constituted by T and, B cells, macrophages, and Th17 cells was reported to be associated to a 
better prognosis in PTC patients [17,23]. On the contrary, poor prognosis was related to the absence in PTC 
nodules of immune-stimulating cells such as CD83-positive mature leucocytes and activated DCs [34]. 
Divergent reports, however, have to be mentioned. In fact, the presence in PTC and metastatic nodes of T 
cells, macrophages, pDCs, and T reg cells was associated to increased tumor progression, invasion, node 
metastasis, and an overall decreased cancer-related survival [37].  
The relationship between thyroid immunity and tumor development is, therefore, pretty intricate. Which 
between the two is the cause and which the consequence of the other has definitely not yet been clarified. 
 
Since PTC and HT can be synchronous, it was suggested that the neoplasia could be induced by 
inflammation. It was suggested that patients with prolonged exposure to inflammation have a higher risk to 
develop cancer [38]. This hypothesis is supported by several observations. Higher concentrations of pro-
inflammatory cytokines with growth factor activity (e.g., IL-17, IFN- -
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thyroiditis [39]. Furthermore, thyroid cells possess hydrogen peroxide (H2O2), one of the naturally occurring 
reactive oxygen species (ROS). ROS have an interesting role being able to induce DNA damage and promote 
the epithelial to mesenchymal transition [40]. Inflammation can imbalance between neutralized and un-
neutralized H2O2, supporting the hypothesis of ROS-dependent inflammation-induced thyroid cancer. Last, 
less destructive thyroiditis (euthyroid, or not fully hypothyroid) seems to have a higher risk for PTC than 
destructive thyroiditis [38]. 
 
Since in PTC immune cell infiltration was related to a better prognosis, the existence of antitumor immune 
response was suggested. This could be also supported by the observation that approximately twofold higher 
concentration of anti-Tg and anti-TPO antibodies can be found in the peripheral blood of PTC patients 
compared to the general population [41]. The induced antitumor immune response should be due to the 
presence of papillary thyroid microcarcinomas that share with PTC a similar gene expression profile [42]. 
 
Any alteration of the immune system capacity to distinguish between self and non-self antigens may result 
either in autoimmunity or in cancer. PTC is able to trigger a number of immune-escape mechanisms that 
correlate with its aggressiveness. It was reported that thyroid tumor cells upregulate cytokines such as IL-4 
and IL-10 [43]. IL-4 reduces the proliferation and impairs the function of cytotoxic CD8+ T cells. PTC-
derived DCs favor the differentiation of CD4+ T cells into T reg cells [44] that are increased in more 
aggressive PTC and node metastasis [37]. T reg cells are able to suppress NK cell functions. Moreover, 
specific surface molecules could be involved in tumor growth despite the immune response. As far as 
humoral immune response is concerned, elevated anti-TPO antibodies were suggested to have a protecting 
role in patients with thyroiditis [38], while anti-Tg antibodies could be a risk factor for PTC [45].  
 
Iodine, autoimmunity and cancer 
Iodine intake is a primary determinant of thyroid disorders. As reported above, iodine intake is a primary 
determinant of thyroid disorders; in contrast, its role in thyroid cancer is still debated. HT appears to be 
worsened by iodine intake [46]; in fact, increased levels of thyroid antibodies result after iodine replacement 
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[47]. The proposed mechanism is an increase in thyroglobulin immunogenicity, as a consequence of the 
presentation of a cryptic pathogenic peptide induced by iodination [48].  
As far as the role of iodine in thyroid cancer is concerned, several authors suggest that iodine intake may 
contribute to PTC increased incidence observed in countries with iodized salt programs [49]; others report 
that thyroid cancer is linked to iodine deficiency, as the incidence of thyroid cancer is higher in nodular 
goiter [50]. Animal studies suggest that iodine deficiency can favor thyroid carcinogenesis [51]; on the 
contrary, iodine excess appears to be a weak promoter [52]. However, most of the studies were conducted by 
inducing profound iodine deficiency and excess more severe than those found in human diets. 
As far as studies in humans are concerned, they mainly deal with the effect of salt iodization introduction or 
level increase on the PTC/FTC ratio, and on the percentage of anaplastic thyroid cancer. They report an 
increase in the PTC/FTC ratio [53], and a decrease of ATC [54]. 
 
Genetic alterations 
Genetic alterations may represent a link explaining the coexistence between PTC and thyroid autoimmune 
diseases.  
Molecular studies have shown that RET/PTC rearrangements occur in 3-60% of PTC cases with an overall 
prevalence depending on geographic factors and radiation exposure [55]. They are the result of the fusion of 
the RET tyrosine kinase domain with the N-terminals of other genes (H4/CCD6 in RET/PCT1; 
RFG/NCOA4 in RET/PTC3). The rearrangement determines the ligand-independent activation of the 
tyrosine kinase domain and results in the increased expression of genes involved in proliferation and 
survival. RET/PTC rearrangements are present in about 90% of AITDs [56]; patients exposed to radiation 
from the Chernobyl nuclear disaster often develops RET/PTC induced papillary tumors associated with 
autoimmune thyroiditis [57]; finally, transgenic mice engineered to express RET/PTC develop papillary 
carcinomas and chronic thyroiditis [58]. Two different hypothesis support the role of RET/PTC as a link 
between PTC and autoimmune thyroiditis. The first theory is that oncogenes responsible for cell neoplastic 
transformation elicit an inflammatory pro-tumorigenic microenvironment. In fact, Borello et al [59] 
demonstrated that RET/PTC1 oncogene, when exogenously expressed in primary normal human thyrocytes, 
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induces the expression of a large set of genes involved in inflammation and tumor invasion, including 
chemokines (CCL2, CCL20, CXCL8, and CXCL12), chemokine receptors (CXCR4), cytokines (IL1B, CSF-
1, GM-CSF, and G-CSF), matrix-degrading enzymes (metalloproteases and urokinase-type plasminogen 
activator and its receptor), and adhesion molecules (L-selectin). In this context, other authors demonstrated 
that RET/PTC3-thyrocytes express high levels of pro-inflammatory cytokines and proteins involved in the 
immune response [60] suggesting that RET/PTC oncoproteins may be directly involved in the early 
modulation of the immune response and may account for the chronic inflammatory infiltrates and chronic 
inflammatory thyroiditis, which can be observed in 20–50% of PTC cases. Moreover, gene expression 
studies in cellular systems showed that not only RET/PTC but also RAS and BRAF proteins, all belonging to 
the RET-PTC/RAS/BRAF/ERK pathway, and whose mutations are present in FTC and PTC, are able to 
induce the up-regulation of chemokines, which in turn could contribute to neoplastic proliferation, survival 
and migration [61].  
The second hypothesis is that that inflammation might facilitate the RET/PTC rearrangement. According to 
this hypothesis, free radical production, cytokine secretion, cellular proliferation as well as other phenomena 
related to inflammation might predispose to the rearrangement in follicular cells. Based on the results of 
these studies, a link between a transforming human oncogene, inflammation, and malignant behavior has 
been suggested. However, other studies disagree about the meaning of this link. Nikiforova and colleagues 
showed that RET/PTC rearrangements were detected only in PTC not associated with thyroiditis [62]. 
Rhoden and colleagues reported that only few follicular cells, expressing very low levels of RET/PTC, were 
detected in Hashimoto’s thyroiditis, thus suggesting that RET/PTC expression does not necessarily predicts 
the development of a PTC in patients with thyroiditis [63].  
Beyond RET/PTC, other gene alterations have been suggested as links between thyroid cancer and 
autoimmune thyroiditis. Unger et al [64] demonstrated that p63 protein was commonly expressed in PTC and 
in Hashimoto’s thyroiditis. p63 regulates the stem cell phenotype in squamous epithelia and it is strongly 
expressed in the basal layer, the stem cell reservoir of squamous epithelia [65]. Authors suggested that p63 
expression may be a potential pathobiologic link between the two disorders. 
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Larson et al [66] demonstrated a 43.8% incidence of autoimmune thyroiditis and associated WTDC. As the 
PI3K/Akt pathway plays a critical role in the balance between cell survival and apoptosis and the 
inflammatory response by activating chemokine receptors and promoting leukocyte migration, authors 
evaluated the role of the PI3K/Akt pathway in autoimmune thyroiditis and associated cancer. As they 
observed increased p-Akt, Akt1 and Akt2 expression in areas of thyroiditis and thyroid cancer compared to 
normal surrounding thyroid tissue, they suggested a possible molecular mechanism involving PI3K/Akt in 
the link between HT and WTDC.  
 
Microchimerism 
The presence in the same organism of cells derived from two different individuals is known as 
“microchimerism”, a phenomenon which primarily occurs during pregnancy. The passage of cells from the 
fetus to the mother is called fetal cell microchimerism (FCM), whereas that occurring from the mother to the 
fetus is named maternal cell microchimerism (MCM). As autoimmune thyroiditis appears to improve during 
pregnancy and to worsen after childbirth [67], several studies focused on FMC in AITDs.  Klintschar et al. 
[68] demonstrated the presence of FMC in HT patients and intrathyroidal FMC were detected in GD [69]. 
Nevertheless, other authors failed to demonstrate and association between microchimerism and thyroid 
autoimmunity [70].  
As well, FMC has been studied in thyroid cancer. Cirello et al [71] detected FMC in 47.5 % of PTC of 
women with a previous male pregnancy; being FMC cells more represented in the tumor tissue with respect 
to normal section. Interestingly, FMC of both tumor and normal tissues expressed thyroglobulin, whereas 
only FMC present in the tumor tissue stained with CD45, a marker of hemopoyetic cells. Finally, to identify 
their function, authors stained Tg+ and CD45+ cells for the major histocompatibility complex II (MHCII), 
which is a marker of antigen-presenting cells. Both Tg+ and CD45+ male cells resulted negative for MHCII 
antigens; therefore, authors concluded that that Tg+/MHCII- male cells could have a role in tissue repair and 
that CD45+/MHCII- male cells could be NK cells with a role in the initiation of a cytotoxic reaction toward 
maternal malignant cells, on the whole indicating a protective role of microchimerism in thyroid cancer. 
Nevertheless, a possible causative role of FMC in thyroid cancer cannot be excluded, as CD45+/MHCII- 
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male cells could alternatively be tumors associated macrophages, whose density is considered a marker of 
decreased survival in thyroid cancer [72].  
 
Conclusions 
Even though we are totally aware of the pathogenetic relationship between autoimmune thyroiditis and PTC, 
despite the bulk of information that has been accumulating over the last decade, our knowledge about the 
involved mechanisms and the flow direction (thyroiditis towards tumor or tumor towards thyroiditis or tumor 
and thyroiditis) is still poor. Many characters are playing in both pieces, as reported in Figure 2, but no final 
has been written yet. We look forward to future enlightening about the interplay between PTC and AITDs 
that could be the rational to design an accurate immunotherapy of thyroid cancer. 
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Figure 1 – Cancer and Immune System: from Immuno Surveillance to Immune 
Escape
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Figure 2 – Autoimmune Thyroiditis and Papillary Thyroid Cancer: cellular and molecular 
characters
 
 
 
 
 
